Kocefan

Ceftriaxone, the active ingredient in Kocefan, is a third‑generation cephalosporin presented as an injectable solution for intravenous use. It treats a broad spectrum of bacterial infections in both adult and pediatric patients, including pneumonia, meningitis, gonorrhea, urinary tract infections, and sepsis.

GNH USA supplies Kocefan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution, ensuring timely delivery and regulatory compliance across multiple markets.

Kocefan (ceftriaxone) is indicated for bacterial infections affecting various organ systems.

- Community‑acquired pneumonia: effective eradication of susceptible Streptococcus pneumoniae and other common pathogens. - Bacterial meningitis: rapid bactericidal activity in cerebrospinal fluid to treat meningococcal and pneumococcal infections. - Gonorrhea: single‑dose therapy for uncomplicated Neisseria gonorrhoeae infections. - Urinary tract infection: clears Gram‑negative uropathogens causing cystitis and pyelonephritis. - Skin and soft‑tissue infection: treats cellulitis and wound infections caused by susceptible bacteria. - Septicemia: systemic therapy for bloodstream infections caused by susceptible organisms.

Ceftriaxone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain or erythema - Diarrhea or loose stools - Nausea or vomiting - Rash or mild pruritus

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Clostridioides difficile‑associated colitis - Biliary sludging or gallbladder pseudolithiasis - Hemolytic anemia in patients with glucose‑6‑phosphate dehydrogenase deficiency

When using Kocefan, clinicians should consider several safety precautions to minimize risk.

- Renal impairment: adjust therapy and monitor renal function. - Hepatic dysfunction: use with caution; monitor liver enzymes. - Neonates and infants <28 days: avoid concurrent calcium‑containing solutions due to precipitation risk. - Hypersensitivity: discontinue immediately if allergic reaction occurs. - Pregnancy and lactation: category B; use only if benefit outweighs potential risk. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Ceftriaxone can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Calcium‑containing IV solutions: may precipitate in lungs and kidneys, especially in neonates. - Biliary sludge‑promoting agents (e.g., high‑dose calcium): increase risk of gallbladder precipitation.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect; monitor INR. - Aminoglycosides: concurrent use may increase nephrotoxicity; assess renal function. - Oral contraceptives: possible reduction in efficacy; advise alternative contraception.